Literature DB >> 35895438

Comparing single-target and multitarget approaches for postoperative circulating tumour DNA detection in stage II-III colorectal cancer patients.

Tenna Vesterman Henriksen1,2, Thomas Reinert1,2, Mads Heilskov Rasmussen1,2, Christina Demuth1,2, Uffe Schou Løve3, Anders Husted Madsen4, Kåre Andersson Gotschalck5, Lene Hjerrild Iversen6, Claus Lindbjerg Andersen1,2.   

Abstract

Circulating tumour DNA (ctDNA) detection for postoperative risk stratification in cancer patients has great clinical potential. However, low ctDNA abundances complicates detection. Multitarget (MT) detection strategies have been developed to increase sensitivity. Yet, empirical evidence supporting performance gains of MT vs. single-target (ST) strategies in a postoperative setting is limited. We compared ctDNA detection in 379 paired plasma samples from 112 stage II-III colorectal cancer patients by ST digital PCR and MT sequencing of 16 patient-specific variants. The strategies exhibited good concordance (90%, Cohen's Kappa 0.79), with highly correlated ctDNA quantifications (Pearson r = 0.985). A difference was observed in ctDNA detection preoperatively (ST 72/92, MT 88/92). However, no difference was observed immediately after surgery in recurrence (ST 11/22, MT 10/22) or nonrecurrence (both 2/34) patients. In serial samples, detection was similar within recurrence (ST 13/16, MT 14/16) and nonrecurrence (ST 3/49, MT 1/49) patients. Both approaches yielded similar lead times to standard-of-care radiology (ST 4.0 months, MT 4.1 months). Our findings do not support significant performance gains of the MT strategy over the ST strategy for postoperative ctDNA detection.
© 2022 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.

Entities:  

Keywords:  circulating tumour DNA; colorectal cancer; liquid biopsy; residual disease

Mesh:

Substances:

Year:  2022        PMID: 35895438      PMCID: PMC9580876          DOI: 10.1002/1878-0261.13294

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   7.449


  35 in total

1.  Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.

Authors:  Jeanne Tie; Yuxuan Wang; Cristian Tomasetti; Lu Li; Simeon Springer; Isaac Kinde; Natalie Silliman; Mark Tacey; Hui-Li Wong; Michael Christie; Suzanne Kosmider; Iain Skinner; Rachel Wong; Malcolm Steel; Ben Tran; Jayesh Desai; Ian Jones; Andrew Haydon; Theresa Hayes; Tim J Price; Robert L Strausberg; Luis A Diaz; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Peter Gibbs
Journal:  Sci Transl Med       Date:  2016-07-06       Impact factor: 17.956

2.  Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.

Authors:  M J M Magbanua; L B Swigart; H-T Wu; G L Hirst; C Yau; D M Wolf; A Tin; R Salari; S Shchegrova; H Pawar; A L Delson; A DeMichele; M C Liu; A J Chien; D Tripathy; S Asare; C-H J Lin; P Billings; A Aleshin; H Sethi; M Louie; B Zimmermann; L J Esserman; L J van 't Veer
Journal:  Ann Oncol       Date:  2020-11-21       Impact factor: 51.769

3.  Determining lower limits of detection of digital PCR assays for cancer-related gene mutations.

Authors:  Coren A Milbury; Qun Zhong; Jesse Lin; Miguel Williams; Jeff Olson; Darren R Link; Brian Hutchison
Journal:  Biomol Detect Quantif       Date:  2014-08-20

4.  Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing.

Authors:  Matilda Holm; Emma Andersson; Emerik Osterlund; Ali Ovissi; Leena-Maija Soveri; Anna-Kaisa Anttonen; Soili Kytölä; Kristiina Aittomäki; Pia Osterlund; Ari Ristimäki
Journal:  PLoS One       Date:  2020-11-25       Impact factor: 3.240

Review 5.  ctDNA and Adjuvant Therapy for Colorectal Cancer: Time to Re-Invent Our Treatment Paradigm.

Authors:  Mahendra Naidoo; Peter Gibbs; Jeanne Tie
Journal:  Cancers (Basel)       Date:  2021-01-19       Impact factor: 6.639

6.  CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.

Authors:  Hiroya Taniguchi; Yoshiaki Nakamura; Daisuke Kotani; Hiroki Yukami; Saori Mishima; Kentaro Sawada; Hiromichi Shirasu; Hiromichi Ebi; Takeharu Yamanaka; Alexey Aleshin; Paul R Billings; Matthew Rabinowitz; Eiji Oki; Ichiro Takemasa; Takeshi Kato; Masaki Mori; Takayuki Yoshino
Journal:  Cancer Sci       Date:  2021-06-07       Impact factor: 6.716

7.  Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing.

Authors:  Christina Demuth; Karen-Lise Garm Spindler; Julia S Johansen; Niels Pallisgaard; Dorte Nielsen; Estrid Hogdall; Benny Vittrup; Boe Sandahl Sorensen
Journal:  Transl Oncol       Date:  2018-08-04       Impact factor: 4.243

Review 8.  Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management.

Authors:  Maha Elazezy; Simon A Joosse
Journal:  Comput Struct Biotechnol J       Date:  2018-10-09       Impact factor: 7.271

9.  Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases.

Authors:  Fotios Loupakis; Shruti Sharma; Madiha Derouazi; Sabina Murgioni; Paola Biason; Mario Domenico Rizzato; Cosimo Rasola; Derrick Renner; Svetlana Shchegrova; Allyson Koyen Malashevich; Meenakshi Malhotra; Himanshu Sethi; Bernhard G Zimmermann; Alexey Aleshin; Solomon Moshkevich; Paul R Billings; Jonathon D Sedgwick; Marta Schirripa; Giada Munari; Umberto Cillo; Pierluigi Pilati; Angelo Paolo Dei Tos; Vittorina Zagonel; Sara Lonardi; Matteo Fassan
Journal:  JCO Precis Oncol       Date:  2021-07-21

10.  Postoperative circulating tumour DNA is associated with pathologic response and recurrence-free survival after resection of colorectal cancer liver metastases.

Authors:  Karen Bolhuis; Iris van 't Erve; Clinton Mijnals; Pien M Delis-Van Diemen; Joost Huiskens; Aysun Komurcu; Marta Lopez-Yurda; Daan van den Broek; Rutger-Jan Swijnenburg; Gerrit A Meijer; Cornelis J A Punt; Remond J A Fijneman
Journal:  EBioMedicine       Date:  2021-07-29       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.